Please use this identifier to cite or link to this item:
|Title:||Lack of association between the A118G polymorphism of the mu opioid receptor gene (OPRMI) and opioid defendence: A meta-analysis|
|Citation:||Pharmacogenomics and Personalized Medicine, 2009; 2(1):9-19|
|Publisher:||Dove Medical Press Ltd|
|Janet K Coller, Julia Beardsley, James Bignold, Yibai Li, Florence Merg, Thomas Sullivan, Timothy C Cox and Andrew A Somogyi|
|Abstract:||Mu opioid receptor (OPRM1) gene variants, particularly the common A118G single nucleotide polymorphism (SNP), are among the most frequently studied candidate genes associated with opioid dependence. However, despite numerous case-control studies and meta-analyses, no definitive conclusion has been reached regarding the association of the A118G SNP and risk of developing opioid dependence. This study aimed to resolve this discrepancy by reinvestigating the association between A118G SNP allelic, and for the first time, genotype frequencies and opioid dependence. A meta-analysis of sixteen case-control studies of opioid dependence was performed with a total of 5169 subjects. No association between the A118G allele (P = 0.23) and genotype (P = 0.34) frequencies and opioid dependence was found. However, significant heterogeneity between studies precluded highly definitive conclusions. In addition, the possibility that other OPRM1 SNPs albeit rarer may influence the risk of opioid dependence remains to be investigated at this level. Nonetheless, despite no evidence of a direct association with risk of dependence, A118G may still influence the pharmacological response to opioids impacting on an individual’s dosage requirements.|
|Keywords:||mu opioid receptor|
|Appears in Collections:||Aurora harvest|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.